Cancer Institute and Hospital, Chinese Academy of Medical Sciences: clinical-trial pipeline
Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the sponsor of 387 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 252 are not yet finished and 12 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 157 |
| Not applicable | 145 |
| Phase 3 | 28 |
| Phase 1/2 | 19 |
| Phase 1 | 18 |
| Early phase 1 | 14 |
| Phase 2/3 | 5 |
| Phase 4 | 1 |
Trials by status
| Status | Trials |
|---|---|
| Recruiting | 146 |
| Unknown | 96 |
| Not yet recruiting | 84 |
| Completed | 38 |
| Active, not recruiting | 22 |
| Terminated | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 357 |
| Gastroenterology and liver | 45 |
| Nephrology and urology | 18 |
| Women's health and obstetrics | 13 |
| Metabolic and endocrine (diabetes, obesity) | 11 |
| Cardiovascular | 7 |
| Dermatology | 5 |
| Haematology | 4 |
| Musculoskeletal | 4 |
| Infectious disease and vaccines | 3 |
| Immunology and rheumatology | 2 |
| Neurology | 2 |
Countries
| Country | Trials |
|---|---|
| China | 330 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-22 | New trial posted | Chaigui Jieyu Qufa Decoction for CRF in Driver Gene-negative Lung Adenocarcinoma Trial |
| 2026-10-19 | New trial posted | Radiotherapy Target Volume in Locally Advanced Esophageal Squamous Cell Carcinoma in the… |
| 2026-10-08 | New trial posted | Clinical Study of Three-dimensional Lattice Radiotherapy Combined With PD-1/PD-L1 Inhibit… |
| 2026-10-07 | New trial posted | The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially… |
| 2026-10-05 | New trial posted | Phase I Study of In Vivo CAR-Tumor Technology for the Treatment of Advanced Malignant Tum… |
| 2026-10-05 | New trial posted | Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immun… |
| 2026-09-25 | New trial posted | Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation E… |
| 2026-09-22 | New trial posted | Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Th… |
| 2026-09-15 | New trial posted | Video-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS Al… |
| 2026-08-28 | New trial posted | A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Re… |
| 2026-08-28 | New trial posted | YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small C… |
| 2026-08-28 | New trial posted | Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT06926751 | Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Soli… | Phase 2 | Recruiting | China |
| NCT06904677 | Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer | Not applicable | Recruiting | China |
| NCT06839560 | Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and… | Phase 2 | Recruiting | China |
| NCT06346041 | Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors | Early phase 1 | Recruiting | China |
| NCT07186868 | QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer | Not applicable | Not yet recruiting | |
| NCT06771596 | Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix | Phase 2 | Active, not recruiting | China |
| NCT07793500 | YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSC… | Early phase 1 | Recruiting | China |
| NCT06791161 | A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2… | Not applicable | Recruiting | China |
| NCT05603078 | A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast… | Not applicable | Recruiting | China |
| NCT06897046 | Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC | Phase 2 | Recruiting | China |
| NCT05188859 | First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothel… | Phase 2 | Recruiting | China |
| NCT06430658 | Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer | Phase 2 | Recruiting | China |
| NCT07156058 | MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer | Not applicable | Recruiting | China |
| NCT05345860 | Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer | Not applicable | Recruiting | China |
| NCT06429839 | Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients | Phase 2 | Recruiting | China |
| NCT06405269 | Effect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients | Not applicable | Recruiting | China |
| NCT07735858 | Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer | Not applicable | Active, not recruiting | China |
| NCT06585878 | A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic… | Not applicable | Not yet recruiting | |
| NCT04423185 | PLATFORM Study of Precision Medicine for Rare Tumors | Phase 2 | Recruiting | China |
| NCT07656116 | Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors | Phase 1 | Recruiting | China |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | Phase 1/2 | Not yet recruiting | China |
| NCT06150365 | Personalized KSX01-TCRT in Patients With Advanced Solid Tumors | Early phase 1 | Recruiting | China |
| NCT05327517 | Surgery or Chemoradiotherapy for Cervical Esophageal Cancer | Not applicable | Recruiting | China |
| NCT07385365 | A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer | Phase 3 | Not yet recruiting | China |
| NCT07239271 | A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escal… | Phase 3 | Not yet recruiting |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Cancer Institute and Hospital, Chinese Academy of Medical Sciences clinical trials: 252 open, 33 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/cancer-institute-and-hospital-chinese-academy-of-medical-sci/, data as of 2026-10-25.